BioCentury
ARTICLE | Product Development

Moderna’s Bancel highlights speed, flexibility of mRNA platform as COVID-19 vaccine heads to Phase II

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

May 8, 2020 1:42 AM UTC
Updated on May 8, 2020 at 4:34 AM UTC

As Moderna readies a Phase II trial of its COVID-19 vaccine just 12 weeks after the virus was sequenced, CEO Stéphane Bancel told BioCentury that the speed of the company mRNA platform could also be an advantage in tackling viral mutations. The biotech, whose shares continued to climb Thursday, also bolstered its team by adding a trio of infectious disease veterans.

Moderna Inc. (NASDAQ:MRNA) gained $4.24 to $53.19 Thursday, bringing its market cap to $19.7 billion. The company has seen its value almost triple in just over two months. ...

BCIQ Company Profiles

Moderna Inc.